NicOx SA of France said it has raised €100 million in a two-step capital increase giving it the financial means to set up a sales force in the US to help commercialise its lead anti-inflammatory drug, naproxcinod, which is being reviewed by the FDA.
NicOx SA of France said it has raised €100 million in a two-step capital increase giving it the financial means to set up a sales force in the US to help commercialise its lead anti-inflammatory drug, naproxcinod, which is being reviewed by the FDA.